PRKAA1 and metabolic dysfunction-associated steatotic liver disease: Liraglutide, an agonist of GLP-1R, can increase acetyl-CoA carboxylase (ACC) phosphorylation through activation of AMPK, which in turn attenuates Erastin- or RSL3-induced cellular ferroptosis in the presence of high glucose, suggesting that Liraglutide ameliorates T2DM-associated NAFLD by inhibiting ferroptosis through activation of AMPK/ACC signaling [157].